NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Price, News & Analysis $11.26 +0.02 (+0.13%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Anika Therapeutics Stock (NASDAQ:ANIK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Anika Therapeutics alerts:Sign Up Key Stats Today's Range$11.08▼$11.3150-Day Range$10.53▼$14.8552-Week Range$10.47▼$29.12Volume28,808 shsAverage Volume73,342 shsMarket Capitalization$161.54 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingStrong Buy Company Overview Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts. Read More Anika Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreANIK MarketRank™: Anika Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 196th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingAnika Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Anika Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anika Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.15% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Anika Therapeutics has recently increased by 5.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.6 / 5Environmental Score-2.01 Percentage of Shares Shorted3.15% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Anika Therapeutics has recently increased by 5.01%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Anika Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ANIK on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.64% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Anika Therapeutics' insider trading history. Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Stock News HeadlinesAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1 hour ago | globenewswire.comAnika Therapeutics stockholders approve incentive plan amendment and elect directorsJune 25, 2025 | investing.comHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.July 3 at 2:00 AM | Timothy Sykes (Ad)Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comCompany News for May 12, 2025May 12, 2025 | msn.comAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | globenewswire.comAnika Therapeutics (ANIK) Stock Maintains "Outperform" Rating Despite PT Adjustment | ...May 12, 2025 | gurufocus.comAnika Therapeutics (ANIK) Sees Target Price Adjustment Amid Future Growth Prospects | ANIK ...May 12, 2025 | gurufocus.comSee More Headlines ANIK Stock Analysis - Frequently Asked Questions How have ANIK shares performed this year? Anika Therapeutics' stock was trading at $16.46 at the start of the year. Since then, ANIK stock has decreased by 31.6% and is now trading at $11.2650. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics Inc. (NASDAQ:ANIK) posted its quarterly earnings data on Wednesday, March, 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.13. The biotechnology company had revenue of $30.60 million for the quarter, compared to the consensus estimate of $29 million. Anika Therapeutics had a negative net margin of 41.28% and a negative trailing twelve-month return on equity of 7.22%. Read the conference call transcript. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings3/12/2025Today7/03/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ANIK CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees300Year Founded1992Price Target and Rating Average Stock Price Target$20.00 High Stock Price Target$21.00 Low Stock Price Target$19.00 Potential Upside/Downside+77.5%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.38 million Net Margins-41.28% Pretax Margin-3.43% Return on Equity-7.22% Return on Assets-5.64% Debt Debt-to-Equity RatioN/A Current Ratio5.73 Quick Ratio4.53 Sales & Book Value Annual Sales$119.91 million Price / Sales1.35 Cash Flow$0.10 per share Price / Cash Flow110.39 Book Value$10.51 per share Price / Book1.07Miscellaneous Outstanding Shares14,340,000Free Float12,959,000Market Cap$161.54 million OptionableOptionable Beta0.64 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ANIK) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.